Latest News

Story

Advent Life Sciences sells portfolio company KaNDy Therapeutics to Bayer AG in deal worth up to USD975m

Advent Life Sciences sells portfolio company KaNDy Therapeutics to Bayer AG in deal worth up to USD975m

Venture capital firm Advent Life Sciences has sold its portfolio company, KaNDy Therapeutics (KaNDy), to Bayer AG for an upfront consideration of USD425 million plus potential milestone payments of up to USD 450 million until launch followed by potential additional triple digit million sales milestones payments.